Upload
dinhdieu
View
385
Download
12
Embed Size (px)
1September 19, 2016
Process Validation
Guidelines
by
Pramote Cholayudth
Thai Industrial Pharmacist Association (TIPA)
2
Process Validation References Hierarchy
Approaches & Strategies
Industry Guidances
Industry Standards
Regulatory Guidelines
Law
3
Process Validation (PV) Objective
PV is performed to:
Confirm and register a manufacturing process at
FDA (Law objective)
Prove, confirm and release a manufacturing
process (QA objective)
PV is not performed once but continuously in a
‘lifecycle’ rather than ‘traditional’ approach
PV data is determined as ‘process release’
data while routine QC data is ‘product release’
data (lot by lot)
4
GMP Regulation: Process Validation
In the Thai FDA GMP Regulations (BE 2554):
The definitions for PV and PV approaches are
given
Qualification and Validation including PV
requirements are described in Chapter 12 (PIC/S
Annex 15, 1 September 2009)
The new revised/expanded version of PIC/S
Annex 15 was issued on 1 October 2015 and
already translated to Thai version
Retrospective approach is no more acceptable
5
Regulatory Guidelines: Process Validation
PIC/S GMP Guidelines and Annexes
GMP Guidelines, Annexes and Recommendations
EU Guidelines
WHO Guidelines
FDA Guidelines
PV: General Principles and Practices
A draft PV guidance was withdrawn in Aug 2013
ICH Guidelines
ASEAN PV Guidelines
6
Industry Standards: Process Validation
United States Pharmacopeia (USP)
British Pharmacopoeia (BP)
International Pharmacopeia (IP)
European Pharmacopeia (EP)
Japanese Pharmacopeia (JP)
Thai Pharmacopeia (TP)
ASTM E2709 & E2810
Others
7
Industry Guidances: Process Validation
Thai FDA PV Guide - now under drafted version
PDA TR # 60: Process Validation: A Lifecycle
Approach
ISPE PQLI Guide Series
ISPE PQLI Guide: Overview of Product Design,
Development and Realization – A Science- and
Risk-Based Approach to Implementation
ISPE PQLI Guide: Part 4 – Process Performance
and Product Quality Monitoring System
8
Recognized Approaches: Process Validation
Traditional Approach
Prospective Approach
Concurrent Approach
Retrospective Approach
Lifecycle Approach
Risk-Based Approach
Science-Based Approach
Bracketing Approach
9
Current Process Validation Approaches
Traditional Approach to Process Validation
Prospective approach
Concurrent approach
Lifecycle Approach to Process Validation
Stage 1: Process design
Stage 2: Process qualification
Process facility, utilities and equipment qualification
Process performance qualification (= Prospective PV)
Stage 3: Continued process verification (CPV)
10
Lifecycle Approach to Process Validation
11
PV Supporting Approaches
Science-based approach
Based on the reason why – e.g. the manufacturing
scale is the outcome of lab & pilot scale, CPP is
the outcome of robustness and optimization study
Risk-based approach
Based on the critical aspects involved – e.g. critical
manufacturing steps, CPP and CQA are taken into
account in PV
Common-sense based approach – focused on
justified common sense
12
Process Validation Strategies
PV ‘strategy’ is flexible while PV ‘approach’ is
not – i.e. strategy related to the number of PV
batches can be kept to a minimum as follows:
Traditional approach
A minimum of 3 PV batches
Lifecycle approach
PPQ batches – the number is to be pre-estimated
CPV batches – the number is to be pre-estimated
13
Process Coverage
As far as ‘process confirmation’ is involved, the
concept of process representativeness i.e.
Process Coverage is to be applied:
In traditional approach
If using statistics-based acceptance criteria (e.g.
Bergum method), using 3-PV batch strategy may
provide the coverage of NLT 50% i.e. at least 50%
of the normal batches is represented by PV
If using none of the powerful statistical ones, the
coverage is not measurable !!
14
Process Coverage
In lifecycle approach
PPQ batches – the number is to be pre-estimated
CPV batches – the number is to be pre-estimated
Such a pre-estimation is illustrated in tables below
The detail on how to calculate the number of PPQ
and CPV batches (including Process Coverage) is
described in TIPA Journal entitled: หมดยคุของ Magic “3 Batches” แลว้ – เป็นแค่วาทกรรมหรือวา่เป็นความจริง
15
Traditional Approach
16
In-Process Control (e.g. SPC)
Optimized Condition
Input Process Output
Development Background
Manufacturing Background
Consistent Quality
Controlled Materials
Total Process: Integrated View(Development To Manufacturing Scale)
17
Man
MethodsMaterials
Environment
Machine
Measurement
Input Process Output
Input
Variables
Output Response
(Quality Attributes)
Process
Parameters
Manufacturing Process: Integrated View(Manufacturing Scale)
18
Batch # 2
NC Rate = 1.0%
Batch # 3
NC Rate = 1.1%
Batch # 1
NC Rate = 0.9%
Process
NC Rate = 1%
Sample 1 = 0.9%
Sample 2 = 1.0%
Sample 3 = 1.1%
AV = 1.0%
AV = 0.9%
Sample 1 = 0.8%
Sample 2 = 0.9%
Sample 3 = 1.0%
AV = 1.1%
Sample 1 = 1.0%
Sample 2 = 1.1%
Sample 3 = 1.2%
Average = 1%NC Rate: Nonconforming Rate
NC Rates in Samples
Average = 1%
Manufacturing Process: Spread View
19
Test Result 1
Test Result 2
Test Result 3
PV Bat. # 1
PV Bat. # 2
PV Bat. # 3Test Result 1
Test Result 2
Test Result 3
Test Result 1
Test Result 2
Test Result 3
Validation Test Results
Validated Process
Process Validation: Process Confirmation Using PV Batches # 1, 2 & 3
Validation test results are, for example, assay, content uniformity, &
dissolution. These are called Critical Quality Attributes (CQAs).
20
Lifecycle Approach:
PPQ vs. CPV
21
‘Number of PPQ Batches’ Strategy
% Confidence % Uncoverage % Coverage No. of Lots nL
89% 67 33 2
88% 50 50 3
87% 40 60 4
87% 33 67 5
87% 25 75 7
87% 20 80 9
87% 15 85 12
86% 10 90 19
86% 5 95 39
PDA TR # 60: Table 8.1.2-1
22
‘Number of CPV Batches’ Strategy
ConfidenceConformance
RateAccept # nL
% Actual Confidence
90% 0 7 52%
95% 0 14 51%
99% 0 69 50%
90% 0 22 90%
95% 0 45 90%
99% 0 230 90%
90% 0 29 95%
95% 0 59 95%
99% 0 299 95%
50%
90%
95%
PDA TR # 60: Table 8.1.6-1
23
PPQ vs. CPV Plan Matrix
24
PPQ & CPV Plan (PDA Table 8.1.2-1 Modified)
Validation Stage
Sampling Plan nLAccept
#% Cum.
Coverage% Actual
ConfidenceStatistical
Tools
PPQ Tightened 3 0 50% 88%
Stringent 4 0 75% 87%
Normal 35 0 95% 88%CpK, Control Chart
PPQ Tightened 4 0 60% 87%
Stringent 3 0 75% 87%
Normal 31 0 95% 86%CpK, Control Chart
PPQ Tightened 5 0 67% 87%
Stringent 0 0 0% 0%
Normal 35 0 95% 87%CpK, Control Chart
CPV
CPV
CPV
Tolerance intervals, CpK
Tolerance intervals, CpK
Tolerance intervals, CpK
25
PPQ & CPV Plan (PDA Table 8.1.6-1 Modified 1)
Validation Stage
Sampling Plan nLAccept
#% Lot
Conf. Rate% Actual
ConfidenceStatistical
Tools
PPQ Tightened 7 0 90% 52%
Stringent 14 0 95% 51%
Normal 69 0 99% 50%CpK, Control Chart
PPQ Tightened 22 0 90% 90%
Stringent 45 0 95% 90%
Normal 230 0 99% 90%CpK, Control Chart
PPQ Tightened 29 0 90% 95%
Stringent 59 0 95% 95%
Normal 299 0 99% 95%CpK, Control Chart
CPV
CPV
CPV
Tolerance intervals, CpK
Tolerance intervals, CpK
Tolerance intervals, CpK
26
PPQ & CPV Plan (PDA Table 8.1.6-1 Modified 2)
Validation Stage
Sampling Plan nLAccept
#% Lot
Conf. Rate% Actual
ConfidenceStatistical
Tools
PPQ Tightened 7 0 90% 52%
Stringent 15 0 90% 90%
Normal 7 0 90% 95%CpK, Control Chart
PPQ Tightened 14 0 95% 51%
Stringent 31 0 95% 90%
Normal 12 0 95% 95%CpK, Control Chart
PPQ Tightened 69 0 99% 50%
Stringent 156 0 99% 90%
Normal 64 0 99% 95%CpK, Control Chart
CPV
CPV
CPV
Tolerance intervals, CpK
Tolerance intervals, CpK
Tolerance intervals, CpK
27
PPQ & CPV Plan (Recommended)
Option #
Validation Stages
Sampling Plans# of PV
LotsAccept
#Process
Coverage (%)Confidence Level (%)
PPQ Tightened 3 0 50% 88%
Stringent 4 0 75% 87%
Normal 15 0 90% 90%
PPQ Tightened 4 0 60% 87%
Stringent 3 0 75% 87%
Normal 22 0 90% 95%
PPQ Tightened 5 0 67% 87%
Stringent 0 0 0% 0%
Normal 39 0 95% 90%
PPQ Tightened 7 0 75% 87%
Stringent 0 0 0% 0%
Normal 50 0 95% 95%
CPV
CPV
CPV
CPV
1
2
3
4
28
Sampling Plans Involved in PPQ/CPV
Since product quality parameters are not
available online, so the off-line sampling (and
testing) plans (MIL-STD) are applied:
Tightened sampling plan e.g. validation sampling
plans
Stringent sampling plan – i.e. normal sampling
with tightened evaluation (e.g. using CpK)
Normal sampling plan – QC & IPC sampling plans
Reduced sampling plan – not applicable in
pharmaceutical industry
29
Process Validation References Hierarchy(Non-Sterile Products)
Traditional & QbD-Based Lifecycle Approaches
(Strategy, Sampling Plan, Accept. Criteria, Stat. Analysis)
Industry Guidances
(PDA TR # 59&60, ISPE PQLI Guide Series)
Industry Standards
(USP, BP, ASTM E2709/E2810)
Regulatory Guidelines
(PIC/S,FDA,ICH,ASEAN)
Law GMP Reg.
30
Any Question?